Cellectar Biosciences
Logotype for Cellectar Biosciences Inc

Cellectar Biosciences (CLRB) investor relations material

Cellectar Biosciences Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Cellectar Biosciences Inc
Q3 2026 earnings summary10 Nov, 2026

Executive summary

  • Q3 progress centered on iopofosine I-131 for relapsed/refractory WM, with post-BTK inhibitor data supporting the planned accelerated-approval strategy.

  • Confirmatory Phase 3 preparation advanced, including site activation; a Phase 1b WM dosimetry study began, and CLR 125 development continued.

Financial highlights

  • Q3 2026 R&D expense was $5.44M vs. $2.5M in Q3 2025, reflecting Phase 3 preparation and increased CLR 125 trial activity.

  • Q3 2026 G&A expense was $2.67M vs. $2.3M in Q3 2025, primarily from higher professional fees and personnel costs.

  • Q3 operating expenses and operating loss were $8.10M vs. $4.85M; net loss was $7.97M vs. $4.44M, or $0.46 vs. $1.41/share.

  • 9M 2026 operating expenses were $21.09M vs. $17.29M; net loss was $20.56M vs. $16.50M, or $1.81 vs. $7.82/share.

Outlook and guidance

  • First patient dosing in the randomized Phase 3 WM trial is targeted for Q1 2027; the trial plans ~100 patients per arm, with enrollment projected to take 18–24 months after first enrollment.

  • Accelerated NDA submission is targeted for H1 2027 and may occur at or after Phase 3 initiation; enrollment must be ongoing at the FDA decision. Full approval depends on superior PFS against a comparator.

  • Phase 1b WM dosimetry is expected to assess 20–30 newly diagnosed and relapsed patients; initial CLR 125 dosimetry and safety data were expected at a Q4 2026 medical meeting.

  • CLR 225 is Phase 1-ready, but trial initiation remains subject to corporate strategy.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Cellectar Biosciences earnings date

Logotype for Cellectar Biosciences Inc
Q4 202612 Mar, 2027
Cellectar Biosciences
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Cellectar Biosciences earnings date

Logotype for Cellectar Biosciences Inc
Q4 202612 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Cellectar Biosciences Inc (CLRB) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer. Leveraging its proprietary phospholipid drug conjugate (PDC) delivery platform, Cellectar aims to develop targeted therapies designed to enhance treatment outcomes by selectively delivering cancer-killing agents to tumor cells, minimizing the impact on normal tissues. The company is headquartered in Florham Park, New Jersey, and its shares are listed on the Nasdaq.